OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

Shareholder Tools

Latest News
OpGen Announces Closing of $3.38 Million Registered Direct Offering
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
OpGen Announces $3.38 Million Registered Direct Offering

btn News

See All News

Upcoming Events
More events are coming soon.

btn Events

See all events